AMRI cutting jobs as it absorbs EU API maker

AMRI expanded in Europe recently with its $358 million (€315 million) move to buy Italy-based API maker Prime European Therapeuticals, picking up manufacturing facilities in both Europe and the U.S. With the deal now closed, AMRI is restructuring and it is costing some jobs.

The Albany, NY-based AMRI ($AMRI) last week made a filing with the SEC that says it is restructuring “certain operations in the United States and Europe.” The CDMO did respond to a request for comment and provided few details in the filing.

It did say it will take a charge of between $5.7 million and $7.3 million in “cash and non-cash charges related to a reduction in force and other transition activities.” AMRI said it expects most of the changes and the charges to occur in H2.

Conference

The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

In May, AMRI announced that it had a deal to acquire the Lodi, Italy-based private company known primarily as Euticals. It got API facilities primarily in Italy, Germany, France and in Springfield, MO.

AMRI CEO William Marth said at the time that it was attracted, in part, by Euticals’ expertise in certain tetracyclines, monobactams, sterile and fermented APIs and controlled substances. AMRI said Euticals was projecting 2016 revenue between $245 million and $255 million.

Earlier in the month, AMRI reported Q2 revenues of $120.8 million, up from about $90 million in the same quarter a year ago but a loss of $21.3 million, or 61 cents a share.

- here’s the SEC filing

Related Articles:
AMRI adds EU API supplier to its stable with $358M deal
AMRI's revenues soar 45% as refocus on contract manufacturing pays off
Manufacturing moves pay off for AMRI

Read more on

Suggested Articles

Leading Indian drugmakers Sun Pharma, Cipla, Aurobindo and Dr. Reddy's are all trying to expand their presences in China.

New Gilead CEO Daniel O’Day has already replaced some key leaders at the company, but he’s not stopping there with the executive overhaul.

The FDA lambasted Strides Pharma in a warning letter after inspectors found testing records in the trash and in bags by a shredder.